{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2018:P7ZGBFAPSQEOLL3IOLYE5QZLOW","short_pith_number":"pith:P7ZGBFAP","canonical_record":{"source":{"id":"1812.10602","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-12-27T02:51:34Z","cross_cats_sorted":[],"title_canon_sha256":"8bcbc9b814e550dc3486e707a0ec7b82542d2df7bb10423cf858d92db786df29","abstract_canon_sha256":"7bcc602aa0720a28be0012ec9499e0857d55567473998007799c2cbe546414cd"},"schema_version":"1.0"},"canonical_sha256":"7ff260940f9408e5af6872f04ec32b758f11fa85f7786d86a9e1659aba052fb9","source":{"kind":"arxiv","id":"1812.10602","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1812.10602","created_at":"2026-05-17T23:57:20Z"},{"alias_kind":"arxiv_version","alias_value":"1812.10602v1","created_at":"2026-05-17T23:57:20Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1812.10602","created_at":"2026-05-17T23:57:20Z"},{"alias_kind":"pith_short_12","alias_value":"P7ZGBFAPSQEO","created_at":"2026-05-18T12:32:43Z"},{"alias_kind":"pith_short_16","alias_value":"P7ZGBFAPSQEOLL3I","created_at":"2026-05-18T12:32:43Z"},{"alias_kind":"pith_short_8","alias_value":"P7ZGBFAP","created_at":"2026-05-18T12:32:43Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2018:P7ZGBFAPSQEOLL3IOLYE5QZLOW","target":"record","payload":{"canonical_record":{"source":{"id":"1812.10602","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-12-27T02:51:34Z","cross_cats_sorted":[],"title_canon_sha256":"8bcbc9b814e550dc3486e707a0ec7b82542d2df7bb10423cf858d92db786df29","abstract_canon_sha256":"7bcc602aa0720a28be0012ec9499e0857d55567473998007799c2cbe546414cd"},"schema_version":"1.0"},"canonical_sha256":"7ff260940f9408e5af6872f04ec32b758f11fa85f7786d86a9e1659aba052fb9","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-17T23:57:20.535182Z","signature_b64":"xp/J4u262aOP0vQ3RO9vSrVSd8OPfTT6DPT4PCWtOC1u5pjMkRlS10Z+7zA5629UFIewN/c0omDfuYDvPbjQAg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"7ff260940f9408e5af6872f04ec32b758f11fa85f7786d86a9e1659aba052fb9","last_reissued_at":"2026-05-17T23:57:20.534642Z","signature_status":"signed_v1","first_computed_at":"2026-05-17T23:57:20.534642Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1812.10602","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-17T23:57:20Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"GEdYNP2XwFlwiIdRRKkryGvV1qWiiQcnZTgvlpHj13r7lIdX4brdLyOcjdZ+SnAUhAj/O8Za9+Cysw4M39M5BA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-03T15:49:00.328737Z"},"content_sha256":"e36a41a3efe478f71e53aa69f546d4389661728b2ed7e3ffbf756149cefe7a4d","schema_version":"1.0","event_id":"sha256:e36a41a3efe478f71e53aa69f546d4389661728b2ed7e3ffbf756149cefe7a4d"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2018:P7ZGBFAPSQEOLL3IOLYE5QZLOW","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Structural insights into characterizing binding sites in EGFR kinase mutants","license":"http://creativecommons.org/licenses/by-sa/4.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.MN","authors_text":"Lei Xie, Philip E. Bourne, Zheng Zhao","submitted_at":"2018-12-27T02:51:34Z","abstract_excerpt":"Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important target to treat non-small cell lung cancer (NSCLC). Currently, three generations of EGFR kinase-targeted small molecule drugs have been FDA approved. They nominally produce a response at the start of treatment and lead to a substantial survival benefit for patients. However, long-term treatment results in acquired drug resistance and further vulnerability to NSCLC. Therefore, novel EGFR kinase inhibitors that specially overcome acquired mutations are urgently needed. To this end, we carried out a c"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1812.10602","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-17T23:57:20Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Xq2XtZl2EqAU4AkIzrKsiVS2Y2aSqMTLot2MjvAf0OoUJTuL3Jf5DaKp/YuHTbghh5h2WedbXidSHs6cbFGgAA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-03T15:49:00.329076Z"},"content_sha256":"df1747d7c873f7cc0032f32b9bb282068b80c10a9f710d5c0a3f2083490f52c9","schema_version":"1.0","event_id":"sha256:df1747d7c873f7cc0032f32b9bb282068b80c10a9f710d5c0a3f2083490f52c9"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW/bundle.json","state_url":"https://pith.science/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-06-03T15:49:00Z","links":{"resolver":"https://pith.science/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW","bundle":"https://pith.science/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW/bundle.json","state":"https://pith.science/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW/state.json","well_known_bundle":"https://pith.science/.well-known/pith/P7ZGBFAPSQEOLL3IOLYE5QZLOW/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2018:P7ZGBFAPSQEOLL3IOLYE5QZLOW","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"7bcc602aa0720a28be0012ec9499e0857d55567473998007799c2cbe546414cd","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-12-27T02:51:34Z","title_canon_sha256":"8bcbc9b814e550dc3486e707a0ec7b82542d2df7bb10423cf858d92db786df29"},"schema_version":"1.0","source":{"id":"1812.10602","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1812.10602","created_at":"2026-05-17T23:57:20Z"},{"alias_kind":"arxiv_version","alias_value":"1812.10602v1","created_at":"2026-05-17T23:57:20Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1812.10602","created_at":"2026-05-17T23:57:20Z"},{"alias_kind":"pith_short_12","alias_value":"P7ZGBFAPSQEO","created_at":"2026-05-18T12:32:43Z"},{"alias_kind":"pith_short_16","alias_value":"P7ZGBFAPSQEOLL3I","created_at":"2026-05-18T12:32:43Z"},{"alias_kind":"pith_short_8","alias_value":"P7ZGBFAP","created_at":"2026-05-18T12:32:43Z"}],"graph_snapshots":[{"event_id":"sha256:df1747d7c873f7cc0032f32b9bb282068b80c10a9f710d5c0a3f2083490f52c9","target":"graph","created_at":"2026-05-17T23:57:20Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important target to treat non-small cell lung cancer (NSCLC). Currently, three generations of EGFR kinase-targeted small molecule drugs have been FDA approved. They nominally produce a response at the start of treatment and lead to a substantial survival benefit for patients. However, long-term treatment results in acquired drug resistance and further vulnerability to NSCLC. Therefore, novel EGFR kinase inhibitors that specially overcome acquired mutations are urgently needed. To this end, we carried out a c","authors_text":"Lei Xie, Philip E. Bourne, Zheng Zhao","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-12-27T02:51:34Z","title":"Structural insights into characterizing binding sites in EGFR kinase mutants"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1812.10602","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:e36a41a3efe478f71e53aa69f546d4389661728b2ed7e3ffbf756149cefe7a4d","target":"record","created_at":"2026-05-17T23:57:20Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"7bcc602aa0720a28be0012ec9499e0857d55567473998007799c2cbe546414cd","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-12-27T02:51:34Z","title_canon_sha256":"8bcbc9b814e550dc3486e707a0ec7b82542d2df7bb10423cf858d92db786df29"},"schema_version":"1.0","source":{"id":"1812.10602","kind":"arxiv","version":1}},"canonical_sha256":"7ff260940f9408e5af6872f04ec32b758f11fa85f7786d86a9e1659aba052fb9","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"7ff260940f9408e5af6872f04ec32b758f11fa85f7786d86a9e1659aba052fb9","first_computed_at":"2026-05-17T23:57:20.534642Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-17T23:57:20.534642Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"xp/J4u262aOP0vQ3RO9vSrVSd8OPfTT6DPT4PCWtOC1u5pjMkRlS10Z+7zA5629UFIewN/c0omDfuYDvPbjQAg==","signature_status":"signed_v1","signed_at":"2026-05-17T23:57:20.535182Z","signed_message":"canonical_sha256_bytes"},"source_id":"1812.10602","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:e36a41a3efe478f71e53aa69f546d4389661728b2ed7e3ffbf756149cefe7a4d","sha256:df1747d7c873f7cc0032f32b9bb282068b80c10a9f710d5c0a3f2083490f52c9"],"state_sha256":"2b6518fdcdb0b47e1793060adf25050beac8cac179e47bdfbc80ed3259ba9091"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"FwvWFQEoP59ncVIOLr4YTo/MtmgWOqFlkuN9AmNj2wOqxMu0zlqtDzoP6H1pkeVaY/N/u/QgtchGX/GaYjbRCg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-06-03T15:49:00.330988Z","bundle_sha256":"5e4ac6e8617801d8b7861a2c6a58eee158a23157b2cb7bb2ccb2eb169b48c774"}}